Comparison of metformin and vildagliptin in type 2 diabetes assessed by meal tolerance test

Comparison of metformin and vildagliptin in type 2 diabetes assessed by meal tolerance test - Comparison of metformin and vildagliptin in type 2 diabetes assessed by meal tolerance test

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010543

Enrollment

Registered

2013-04-22

Start date

2013-04-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Hospitalized patients with type 2 diabetes under insulin therapy or oral diabetic agents treatment will be enrolled. Insulin secretion will be evaluated by glucagon test prior to the treatments for th

1.0ng/ml). After fasting blood glucose is controlled to the range from 80mg/dl to 130mg/dl (during pre observation period), either metformin (1000mg/day) or vildagliptin (100mg/day) will be administer

vildagliptin 100mg/day vildagliptin 100mg/day-&gt

metformin 1000mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who meet the following conditions: (1)Age: younger than 75 years old, elder than 20 years old (2)recent HbA1c : less than 12.0%

Exclusion criteria

Exclusion criteria: Patients who falls under any of the following conditions shall be excluded: (1)Type 1 diabetes or type 2 diabetes with insulin-dependent condition (2)severe renal and liver dysfunction (3)unstable pre or proliferative diabetic retinopathy, severe neuropathy (4)past history of the gastrointestinal tract or pancreas operation (5)administered steroid drugs (6)severe infection (7)pregnant or planned pregnant in the near future (8)ineligible for some other medical reasons judged by the investigator

Design outcomes

Primary

Measure	Time frame
Comparison of glucose variability between two treatments by Meal Tolerance Test	—

Secondary

Measure	Time frame
Comparison of serum C-peptide and glucagon levels between two treatments	—

Countries

Japan

Contacts

Public ContactTetsushi Nasu

Naga Municipal Hospital Department of Internal Medicine

soumu@nagahp.jp0736772019

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026